Citigroup upgraded shares of Astellas Pharma (OTCMKTS:ALPMY – Get Rating) from a neutral rating to a buy rating in a research note issued to investors on Sunday, The Fly reports.

Astellas Pharma stock opened at $14.96 on Friday. The firm has a market cap of $27.06 billion, a price-to-earnings ratio of 28.22, a price-to-earnings-growth ratio of 0.64 and a beta of 0.60. Astellas Pharma has a 52 week low of $12.82 and a 52 week high of $16.61. The business’s 50-day moving average price is $14.21 and its 200 day moving average price is $14.48. The company has a quick ratio of 1.29, a current ratio of 1.52 and a debt-to-equity ratio of 0.09.

Astellas Pharma (OTCMKTS:ALPMY – Get Rating) last issued its quarterly earnings data on Monday, February 6th. The company reported $0.27 EPS for the quarter. The company had revenue of $2.85 billion for the quarter. Astellas Pharma had a return on equity of 9.62% and a net margin of 8.78%.  As a group, sell-side analysts anticipate that  Astellas Pharma will post 0.72 earnings per share for the current year.

Astellas Pharma, Inc engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases.

Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.